GeoVax is a biotechnology company specializing in the creation, development, and commercialization of human vaccines to combat HIV/AIDS.
Designed for predominant AIDS virus subtypes using DNA and viral vector technologies, our unique AIDS vaccine technology is designed for use in uninfected people to protect them from AIDS should they be exposed to the HIV-1 virus. GeoVax’s preventive vaccine recently completed Phase 2 safety trials through the US Government sponsored HIV Vaccine Trials Network (HVTN).
Results from preclinical studies demonstrated therapeutic potential for our vaccine. A Phase 1/2 human clinical trial is now underway where the vaccine is being tested as a treatment to reduce the need for drugs in people already infected with HIV.
As a leader in our field, we are committed to progress against the most devastating global disease of our lifetime.